We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
VAV expects with an increased capacity, its lipid raw materials will help pharma companies to add three lakh vials of liposomal amphotericin-B, by August, and six lakh vials by December 2021.